Aptose Biosciences’ (APTO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $2.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a report on Friday, November 29th. They issued a “hold” rating for the company.

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO opened at $0.19 on Tuesday. Aptose Biosciences has a 52-week low of $0.13 and a 52-week high of $2.91. The stock has a market cap of $3.51 million, a P/E ratio of -0.07 and a beta of 1.06. The firm has a 50 day moving average price of $0.34 and a 200 day moving average price of $0.54.

Institutional Trading of Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.